Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline

Purpose: To provide the clinical recommendations for the administration of intravitreal anti-vascular endothelial growth factor (VEGF) drugs especially bavacizumab for ocular vascular diseases including diabetic macular edema, neovascular age-related macular degeneration, myopic choroidal neovascularization, retinal vein occlusion and central serous chorioretinopathy.

Methods: Twenty clinical questions were developed by the guideline technical committee. Relevant websites and databases were searched to find out the pertinent clinical practice guidelines to answer the questions. The technical committee provided possible answers (scenarios) according to the available evidences for each question. All scenarios along with their levels of evidence and the supported articles were sent to the experts for external review. If the experts did not agree on any of the scenarios for one particular clinical question, the technical committee reviewed all scenarios and their pertinent evidences and made the necessary decision. After that, the experts were asked to score them again. All confirmed scenarios were gathered as the final recommendations.

Results: All the experts agreed on at least one of the scenarios. The technical committee extracted the agreed scenario for each clinical question as the final recommendation. Finally, 56 recommendations were developed for the procedure of intravitreal anti-VEGF injection and their applications in the management of ocular vascular diseases.

Conclusion: The implementation of this guideline can standardize the management of the common ocular vascular diseases by intravitreal injection of anti-VEGF agents. It can lead to better policy-making and evidence-based clinical decision by ophthalmologists and optimal evidence based eye care for patients.

Citing Articles

Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe.

Barakat M, Kwong Jr H, Marcon G, OLeary O, Paris L, Schneider P Clin Ophthalmol. 2025; 19:395-406.

PMID: 39931677 PMC: 11809211. DOI: 10.2147/OPTH.S503060.

Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration.

Teo K, Eldem B, Joussen A, Koh A, Korobelnik J, Li X Eye (Lond). 2024; .

PMID: 39379523 DOI: 10.1038/s41433-024-03370-0.

Comparative efficacy of aflibercept and ranibizumab in the treatment of age-related macular degeneration with retinal pigment epithelial detachment: a systematic review and network meta-analysis.

Sun Z, Yang Y, Lin B, Huang Y, Zhou R, Yang C BMC Ophthalmol. 2023; 23(1):473.

PMID: 37990182 PMC: 10664577. DOI: 10.1186/s12886-023-03214-7.

Lost to follow-up of patients who received intravitreal anti-vascular endothelial growth factor therapy to treat four different retina disorders in an individual center in Brazil.

Takahashi V, Balbino M, Ruppert A, de Carvalho L, Seixas R SAGE Open Med. 2023; 11:20503121231199655.

PMID: 37808513 PMC: 10559699. DOI: 10.1177/20503121231199655.

Pemafibrate prevents choroidal neovascularization in a mouse model of neovascular age-related macular degeneration.

Lee D, Nakai A, Miwa Y, Negishi K, Tomita Y, Kurihara T PeerJ. 2023; 11:e14611.

PMID: 36643635 PMC: 9838199. DOI: 10.7717/peerj.14611.

References

Tufail A, Narendran N, Patel P, Sivaprasad S, Amoaku W, Browning A . Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study. Ophthalmology. 2013; 120(9):1944-5.e1. DOI: 10.1016/j.ophtha.2013.06.010. View

Singh R, Srivastava S, Ehlers J, Bedi R, Schachat A, Kaiser P . A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month.... Br J Ophthalmol. 2014; 98 Suppl 1:i22-27. PMC: 4033174. DOI: 10.1136/bjophthalmol-2013-304798. View

McCannel C . Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina. 2011; 31(4):654-61. DOI: 10.1097/IAE.0b013e31820a67e4. View

van der Reis M, La Heij E, de Jong-Hesse Y, Ringens P, Hendrikse F, Schouten J . A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections. Retina. 2011; 31(8):1449-69. DOI: 10.1097/IAE.0b013e3182278ab4. View

Rosenfeld P, Brown D, Heier J, Boyer D, Kaiser P, Chung C . Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1419-31. DOI: 10.1056/NEJMoa054481. View

Abraldes M, Zapata M, Gomez-Ulla F, Garcia-Arumi J . [From scientific evidence to clinical practice: treatment regimens for macular edema secondary to retinal vein occlusion]. Arch Soc Esp Oftalmol. 2013; 87 Suppl 1:54-62. DOI: 10.1016/s0365-6691(12)70052-7. View

Epstein D, Algvere P, von Wendt G, Seregard S, Kvanta A . Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology. 2012; 119(12):2587-91. DOI: 10.1016/j.ophtha.2012.06.037. View

Ding X, Li J, Hu X, Yu S, Pan J, Tang S . Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011; 31(5):838-45. DOI: 10.1097/IAE.0b013e3181f4420d. View

Ahmadieh H, Ramezani A, Shoeibi N, Bijanzadeh B, Tabatabaei A, Azarmina M . Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2007; 246(4):483-9. DOI: 10.1007/s00417-007-0688-0. View

10.

Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R . Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009; 116(10):1943-8. DOI: 10.1016/j.ophtha.2009.07.001. View

11.

Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N . Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117(6):1124-1133.e1. DOI: 10.1016/j.ophtha.2010.02.022. View

12.

Forte R, Cennamo G, Breve M, Chiariello Vecchio E, de Crecchio G . Functional and anatomic response of the retina and the choroid to intravitreal bevacizumab for macular edema. J Ocul Pharmacol Ther. 2011; 28(1):69-75. DOI: 10.1089/jop.2010.0181. View

13.

Funk M, Schmidinger G, Maar N, Bolz M, Benesch T, Zlabinger G . Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina. 2010; 30(9):1412-9. DOI: 10.1097/IAE.0b013e3181e095c0. View

14.

Katibeh M, Pakravan M, Yaseri M, Pakbin M, Soleimanizad R . Prevalence and Causes of Visual Impairment and Blindness in Central Iran; The Yazd Eye Study. J Ophthalmic Vis Res. 2016; 10(3):279-85. PMC: 4687262. DOI: 10.4103/2008-322X.170362. View

15.

Ho A, Scott I, Kim S, Brown G, Brown M, Ip M . Anti-vascular endothelial growth factor pharmacotherapy for diabetic macular edema: a report by the American Academy of Ophthalmology. Ophthalmology. 2012; 119(10):2179-88. DOI: 10.1016/j.ophtha.2012.07.058. View

16.

Yilmaz T, Cordero-Coma M . Use of bevacizumab for macular edema secondary to branch retinal vein occlusion: a systematic review. Graefes Arch Clin Exp Ophthalmol. 2012; 250(6):787-93. DOI: 10.1007/s00417-012-2016-6. View

17.

Thulliez M, Angoulvant D, Le Lez M, Jonville-Bera A, Pisella P, Gueyffier F . Cardiovascular events and bleeding risk associated with intravitreal antivascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol. 2014; 132(11):1317-26. DOI: 10.1001/jamaophthalmol.2014.2333. View

18.

Yang H, Kim J, Kim J, Joe S . Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Am J Ophthalmol. 2013; 156(6):1201-1210.e2. DOI: 10.1016/j.ajo.2013.08.002. View

19.

Wecker T, Ehlken C, Buhler A, Lange C, Agostini H, Bohringer D . Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV. Br J Ophthalmol. 2016; 101(3):353-359. PMC: 5339568. DOI: 10.1136/bjophthalmol-2016-308668. View

20.

Soheilian M, Garfami K, Ramezani A, Yaseri M, Peyman G . Two-year results of a randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus laser in diabetic macular edema. Retina. 2012; 32(2):314-21. DOI: 10.1097/IAE.0b013e31822f55de. View